At NanoCell we develop in vivo gene therapies harnessing our non-viral, DNA-based, cell directed, technology platform. Our goal is to transform the cell and gene therapy field by converting adoptive cell therapies into gene therapies. By doing so, we aim to enhance scalability, affordability, and clinical safety and efficacy outcomes. Ultimately, we are committed to ensuring patients have access to exceptional therapeutic options worldwide.
At the heart of our innovation is the non-viral delivery method, designed to specifically target and modify cells within the patient using therapeutic DNA. Nanocell’s proprietary approach to DNA delivery offers a promising alternative to viral methods, setting a new benchmark in the field.